US OptionsDetailed Quotes

KRON241018C7500

Watchlist
  • 0.05
  • 0.000.00%
15min DelayClose Sep 30 16:00 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

News

Comments

    Jaguar8
    Jaguar8
    Sep 25 07:56
    NEWS
    $Kronos Bio (KRON.US)$
    Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy
    Kronos Bio (Nasdaq: KRON) will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at ACR Convergence 2024 in Washington, DC. The presentation, scheduled for November 18, 2024, will showcase how p300 KAT inhibitionmodulates multiple pro-inflammatory signaling pathways in chronic inflammatory diseases.
    The compa...
    Trytosaveabit
    Trytosaveabit
    Sep 23 08:00
    Update
    $Kronos Bio (KRON.US)$ Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
    4 MINUTES AGO, 8:55 AM EDT
    VIA GLOBENEWSWIRE
    – New data show istisociclib (KB-0742) triggered cell death in preclinical ovarian cancer models of platinum and PARP-inhibitor (PARPi) resistance –
    New PK/PD results demonstrate that istisociclib given at 80mg on a 4 days on/3 days off schedule resulted in sustained downregulati...
    Jaguar8
    Jaguar8
    Sep 23 07:55
    NEWS
    $Kronos Bio (KRON.US)$
    Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian Cancer
    Kronos Bio (NASDAQ: KRON) presented new preclinical data on istisociclib (KB-0742), a CDK9 inhibitor, at the AACR Ovarian Cancer Research Symposium. The data supports the clinical evaluation of istisociclib in advanced ovarian cancer, particularly in platinum and PARP-inhibitor resistant cases.
    Key findings include:
    Istisocic...
    Jaguar8
    Jaguar8
    Jul 23 15:15
    NEWS
    $Kronos Bio (KRON.US)$
    Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian Cancer
    Kronos Bio (NASDAQ: KRON) has dosed the first patient in an expansion cohort of its KB-0742 clinical trial, focusing on platinum-resistant high-grade serous ovarian cancer (HGSOC). The trial uses an 80mg dose on a four-days-on, three-days-off schedule, which cleared the dose escalation phase. This dosing regimen is expected to provi...
    Jaguar8
    Jaguar8
    May 23 16:35
    $Kronos Bio (KRON.US)$
    NEWS
    Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
    Kronos Bio announced new data from its Phase 1/2 trial of KB-0742, presented at the 2024 ASCO Annual Meeting. KB-0742 showed a manageable safety profile with no grade 3/4 neutropenia observed. Dose linear pharmacokinetics were consistent up to 80mg, and increased target engagement was noted at higher doses. The 80mg four-days-on, t...
Read more